1、計 書開計書項簽_ 1. 執結1.1.諾簡稱諾領20112飾質產區AmbrxScripps進術質術開質時續PEG-療產組島劑質公司冊資8100幣1.2.隊隊組別來專專識時隊員隊 質為穩礎1.3.產開PEG飾島 產Ambrx術 這項 術請場專專200880117073.1專飾島應產獨術對組島 進結PEG 進飾臨驗顯競1.4.場脅殺10%I過島 維II30-40%須輔島療2009療場規304預計 來 將15%09100較 08療場15.09%島劑額為 35.46%維33.86%島劑場90%場競產為島劑組島療驗場競遠島額漸擠產時將 給現帶來擊1.5.戰AmbrxScripps3SFDA1-1.1.6

2、.120%1.7.2000Ambrx72036%80040%28014%20010%.30001000200053-...112212331234.2.5.121231234412512342.2.6.Ambrx3. 產3.1.為謝 亂節殺導臟腦腎為殘滲綜嚴階現為飲應遲鈍劇現癲癇癱腦狀島療島質島 細臟內內產島島別對應 III1921FrederickBantingJohn Macleod島應臨療們開識島開規產進場島島島這島 來島結島應臨療島產遠遠滿場這島為 純問題導對產 過應嚴導1982島組島島過腸為產獲組島這島現島場進

3、療場盡組島內島結質為質進給較時內進這僅療還島島領產過 為組島獲諸謝這島階產獲場應場額擴內費對島 進島產鞏療領場.1.-飾島劑3.2.2.劑開報審階3.2.3.穩輕狀.2.5.CN200880117073.1飾 島3.3.術紹諾PEG組島領島 產PEG島過飾來組島產PEG飾島驗階過審規產較飾問題PEGpH細飾應PEG飾過FDA審 進場銷PEG飾顯獲給給療PEG飾質質組質 單進飾飾質PEG飾質顯PEG飾質飾單飾質飾質飾質時飾現純純凈這給產質監帶來難過 監審對質揮PEG須預飾這諾Ambrx開RECode®術這項術腸質細內進標質這 連們對質進飾過 Recode&#

4、174;術們島PEG純凈PEG飾獲飾 島術細節權1詳較場現產們島 產穩飯 輔帶給療驗時們銷對對對應導3.4. 項勢產 線輔3.4.1.專術時對質獨產產線GMP 認證產過嚴 執組產規3.4.2.勢計 將400資對產 進來10-20產規將預計內4.開4.1.術評諾Ambrx開REcode®術質領1999ScrippsPeter G. Schultz時Ambrx創頂級雜Science關術Expandingthe genetic code of腸細內Escherichia coli L Wang. Science, 20014312003Ambrx數獲1250資質場頂級AmbrxRecode

5、®紛紛戰術進開應4.2.術競對開進質計項羅 (Roche)進們開飾質術們術術壘們術難 過術勢內術現競 對4.3.計為創們諾對術們開產 還飾飾飾飾漿飾維請專4-1.飾200580003786.1200980104660.1飾飾 FGF-21200880009653.94.4.計20%銷額進購員費術費4.5.術資過 60020術專應請 專過4.6.術勵術規結諾規簡稱 規規內項 術 專 細節級評詳細帶來損還將權勵勵員對 術進 開5.場5.1.200930415%091000815.09%35.46%33.86%90%5.2.1953WatsonCrickDNAEPO()GeneTech20

6、10Provenge1998200918.57%8.45%:2000200915()9035%8070605030%25%20%40302010015%10%5%0%19981999 2000 200120022003 2004200520062007200820095-1.100%90%80%70%60%50%40%30%20%10%0%2000200820145-2.1002002-2005CAGR18%CAGR17%2006-2009CAGR29%CAGR47%10008006004002000200220032004200520062007200820095-3.2002200518%

7、20062006200929%1537%1528%1005001,0006.IMS2005188.422004167.9812.17%2006213.0913.09%2007242.8313.96%2008272.6712.29%2009300304.0641015%20022008200241.87200885.22006%12025.00%10020.00%8015.00%6010.00%405.00%2000.00%200220032004200520062007200820096-1. 2002-200920.98%98.0617.58%85.274.9515.09%61.9555.8

8、13.68%50.1841.8745.2511.20%11.02%10.90%8.07%200720.98%200813.68%85.2200998.0615.09%4IIII10%II90%30%IIII87208020906-1.60%60/30R250/40%/N/ADegludec6.1.IDF11122.853.4IIIDF20304.38I10%30%II90%37%500500IMS15014.3%200220098%IMS201026%23%CAGR15%-18%8-12%IMS2009-20145-8%CAGR 7.1%14.3%350300250200150100500MA

9、TQ2 2005MATQ2 20106-2.20052010201019931. 9200810.720082008120,200970,201021/6200521/13,1020%,2001,10590.0%4.580.0%43.570.0%60.0%32.550.0%40.0%21.530.0%20.0%10.510.0%00.0%Q2 2005Q3 2006Q4 2007Q1 2009Q2 2010100%0%1%1%2%3%5%90%17%19%16%21%23%15%80%70%60%50%40%81%81%80%80%78%77%30%20%10%0%2009A2010E2011

10、E2012E2013E2014E6-4. 2009201470.00%60.00%50.00%40.00%30.00%20.00%10.00%0.00%Q1 2005Q3 2006Q4 2007Q1 2009Q2 20106-5.64.00%13.00%12.00%5.00%4.00%6.2.20097020-25%201522060%70%25%20094060%100020083.8167200446%600200990006SoloStar5000201220043000300201051300201320..100500-1,000.3.4

11、.7.戰7.1.AmbrxScripps7.2.ISO9000..1.1.=+/=+=+×=+=1-1+=×1-933.09%8-1.18.3315.9329.1143.7745.8310%100%120%113.5/1+120%113.5× 1-10%-33.09% = 438.76/17%220118.2.2010GDP20032005-2.1276278984970.490627.110.120011292279097670.496927.510.7200372.0100657.710.7200572.

12、5106368.111.1200773.0113098.511.620098-3.20052620650240210160IMS51518%58%52025%..8-4.2.:.0067.5407070%.00>>>.1.OTCOTCOTCOTC2.OTC100011RxOTC-5.B38181218331569D16823F6312HA.B.C.D.E.F.G.H.I.ABC70%I3%./2./3.4004.9. 產9.1.PEGSFDAGM

13、PPEGISO9000.10000L200L1.02.0g/LPEG9-1.200 kg/300 kg/10%..11123113112KPI006040410.3.11.財11.1.111231205102060235201110%20%..1.100030001.Ambrx72036%80040%28014%20010%.30001000200011-1.Ambrx36036%10010%11-1.2.23100040001100023300011-2.1001003001001

14、0010010020020020010000%5%20%1-3.3-56.65%11-4.WACC25%25%25%4%14%12.1625 %12.1625%12.1625%15.1.20022008200241.87200885.22006200720.98%200813.68%85.2200998.0615.09%11-5.11.2%11.02%20.98%13.68%15.09%14.39%增長率511-6.52005-200911-7. 200520092011201511-8. 20112

15、01511-9. 2011201538.00%39.33%40.72%42.15%43.63%5655.90480018934.97227246146.24540076500.859050117417.16507511.3.2.PhRMABurrill&Co.71.16%3.28%5.75%7.45%10.24%2011年E2012年E2013年E2014年E2015年E128.31146.78167.89192.06219.6918%81311-10.565.591893.503144.784824.82588907(1

16、1.4.81-198%IRRPtNPV5%11-12.IRR105%102%99%98%96%93%90%IRR81%88%94%98%101%107%113%25%15%5%0%-5%-15%-25%NPV5574.975323.025071.094945.124819.154567.204315.272-1.2468PEGFDA3SFDA12.1.2.”2.2.(IPO),5-72011-201540440.314906212-1.123

17、Ambrx; 2008 7 21 1.1 CN200880117073.1 Ambrx1.21.3 36.0% 2 .1 8.39. 19.2 20114 1 2010.310.410.510.610.710.8A. Ambrx B.English VersionSigning Date:.Signing Place:,ChinaContract No.: China iNovProtein co. (herein after

18、referred to as “Licensee” on the one hand and AmbrxCompany (herein after referred to as “Licensor”) on the other hand;Whereas the patent right of “A modified insulin and its application” is owned by Licensor;Whereas Licensor has the right and agreed to grant Licensee the rights to use, manufacturean

19、d sell the Contract Products of the Patented Technology;Whereas Licensee hope to use the Patented Technology of Licensor to manufacture and sellthe Contract Products;Both partiers authorized representatives, through friendly negotiation, have agreed to enterinto this Contract under the terms as stip

20、ulated below.Section 1 Definitions1.1 Patented Technology means the technology which has been written in Appendix 1 tothe Contract, it was approved by China Patent Office in 2008.7.21 and granted the patent right, thepatent number is.1.2 “Licensor” means Ambrx Company, or the legal representative, o

21、r agency or theproperty successor of the Company.1.3“Licensee” means China iNovProtein Corporation, or the legal representative, oragency or the property successor of the Corporation.1.4“The Contract Products” means the products stipulated in Appendix 2 to the Contract.1.5 “he Contract Factory” mean

22、s the factory which manufactures the Contract Products; itis located inand named as iProte.1.6 “Net Selling Price” means the remaining sum which the selling commercial invoiceprice deducts the packing expenses, transportation expenses, insurance premium, commissions,commercial discounts, taxes and e

23、xpenses for bought out elements and parts etc.1.7 “The Patent Documents” means all related documents covered in Appendix 1 to theContract.1.8“The Date of Coming into Force of the Contract” means the date of ratification of theContract by the competent authorities of both parties, whichever comes lat

24、er.Section 2 Scope of the Contract2.1 Licensee agrees to obtain from Licensor, and Licensor agrees to grant Licensee theright to design, manufacture specification and technical indices of the Contract Products aredetailed in Appendix 2 to the Contract.2.2 Licensor agrees to grant Licensee the licens

25、e and right to design, manufacture, use, selland export the Contract Products in China. The license and right are non-exclusive andtransferable.2.3 Licensor is responsible for providing Licensee with the Patented Documents of theCon- tract products, including the mane, content, application for paten

26、t and number of the patent,etc., the specific documentation is detailed in Appendix1 to the Contract.2.4 In the course of implementation of the Contract, Licensor is under an obligation, uponthe request of Licensee, to provide Licensee at the best favorable price with the tec hnical servicesor some

27、components, spare parts and raw materials which are necessary for manufacturing theContract Products. When the time comes, both parties will sign the new contract through friendlyconsultation.2.5 Licensor agrees to grant Licensee the License and right to use the trade mark ofLicensor, while the comb

28、ined trade mark of both parties and mark the wording productionaccording to Licensor's license on the Contract Products can be also adopted.Section 3 Price of the Contract3.1 Price of the contract shall be calculated on Royalty in accordance with the content andscope stipulated in Section 2 to t

29、he contract and the currency shall be in US Dollars.3.2 Royalty under the contract shall be paid from the 11 month after the date of cominginto force of the Contract in terms of Calendar Year. The date of settling accounts shall beDecember 31 of each year.3.3 Royalty at the rate of 1 % (say 1 percen

30、t) shall be calculated in terms of net sellingprice after the Contract Products are sold in this year, the Contract products which have not beensold shall not include.3.4 The report of the selling quantity, net selling amount of the Contract Products andRoyalty which should be paid last year shall b

31、e submitted to Licensor inn written form byLicensee within 10 (ten) days after the date of settling accounts to Royalty. The specific methodsfor calculating net selling amount and Royalty are detailed in Appendix3 to the Contract.3.5 If Licensor demands to audit the accounts of Licensee, it shall no

32、tice Licensee within10 days after receiving the written notice of Licensee in accordance with Section 3.4 of theContract. The specific content and procedure of auditing accounts are detailed in Appendix 4 tothe Contract.Section 4 Conditions of Payment4.1 Royalty stipulated in Section 3 to the Contra

33、ct shall be affected by Licensee toLicensor through the Bank CBC (here it is the business Bank of Licensee) and the Bank ofLicensor). The Payment shall be settled in US Dollars.4.2 Licensor shall immediately issue the related documents after receiving the writtennotice submitted by Licensee in accor

34、dance with Section 3.4 of the Contract. The royalty shall bepaid by Licensee to Licensor within 30 (thirty) days after Licensee has received the followingdocuments which are provided by Licensor and found them in conformity with the stipulations ofthe Contract:A. Four copies of the statement on calc

35、ulation of the royalty;B. Four copies of the commercial invoice;C. Two copies of the sight draft.4.3 Licensee shall have the right deduct from any of the above mentioned payment thepenalties and/or compensations which Licensor shall pay to Licensee in accordance with thestipulations of the Contract.

36、Section 5 Delivery and Improvement of the Technical Documentation5.1 The Patent name, content and related situation which Licensor applied for the patentfrom China Patent office shall be provided by Licensor to Licensee in accordance with stipulationsin Appendix2 to the Contract.5.2 The Patent Docum

37、ents stipulated in Section 5.1 to the Contract shall be provided byLicensor to Licensee while the Contract is signing (note: Because the Patent Documen6ts areready-made, Licensor shall provide them to Licensee in signing the Contract).5.3 Within the validity period of the Contract, both parties shal

38、l provide each other withthe improvement and development of the Technology related to the Contract Products free ofcharge.5.4 The improved and developed technology shall be owned by the party who improvedand developed the technology; the other party shall be prohibited from applying for the patent,

39、ortransferring to the third party.Section 6 Infringements and Guarantees6.1 Licensor guarantees that Licensor is the legitimate owner of all the PatentedTechnology and Documentation supplied by Licensor to Licensee in accordance with the Contract,and that Licensor is lawful in a position to transfer

40、 all such Technology and TechnicalDocumentation to Licensee. In the course of implementation of the Contract, if any third partyaccuses Licensee of infringement, Licensor shall be responsible for approaching the third partyabout the accusation and bear all the economic and legal responsibilities whi

41、ch may arise.6.2 Licensor guarantees that the Patent covered in the Contract shall be lawful and valid inthe course of implementation of the Contract. If because of Licensor the Patent advanced ceases tobe in force, Licensor shall repay expenses which have been paid by Licensee after the Patent hasc

42、eased to be in force, and plus the interest at the rate of 2 % (say 2 percent) per annum.6.3 Within the validity period of the Contract, Licensor shall pay the cost of maintainingthe Patent on time in accordance with related stipulation of the China Patent Office so as tomaintain the Patent effectiv

43、eness.6.4 In the course of implementation of the Contract, if the legal mature of the Patentconcerned in the Contract has changed, Licensor shall immediately notify Licensee this case inwritten form, then both parties shall solve the problem, and decide the further execution of theContract through f

44、riendly consultation.Section 7 Taxes and Duties7.1 All the taxed and duties in connection with and in the execution of the Contract to beLevied on Licensee by the Government of the People'sin accordance with theTax Laws in effect shall be paid by Licensee.7.2 All the taxes and duties in connecti

45、on with and in the execution of the Contract to belevied on Licensor by the Government of the People'sin accordance with theTax Laws in effect shall be paid by Licensor.Section 8 force Majeure8.1 If either of the contraction parties is prevented from execution the Contract by suchcases of force

46、majeure as war, serious flood, fire, typhoon and earthquake or other cases which areagreed upon by both parties as cases of force majeure, the time for performance of the Contractshall be extended by a period equivalent to the effect of such cases.8.2 The effected party shall notify the other party of the cases of force majeure occurred bytelex or cable as soon as possible and shall send by registered airmail, within 14 (fourteen) daysthereafter,